Car t cell immunotherapy for human cancer

Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia

Maude, S. L., Laetsch, T. W., Buechner, J., Rives, S., Boyer, M., Bittencourt, H., Bader, P., Verneris, M. R., Stefanski, H. E., Myers, G. D., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1709866 · Cited by 5,735 · see citing works

Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia

Maude, S. L., Frey, N., Shaw, P. A., Aplenc, R., Barrett, D. M., Bunin, N. J., Chew, A., Gonzalez, V. E., Zheng, Z., Lacey, S. F., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1407222 · Cited by 5,413 · see citing works

Immune-Related Adverse Events Associated with Immune Checkpoint Blockade

Postow, M. A., Sidlow, R., & Hellmann, M. D. (2018) · New England Journal of Medicine · doi:10.1056/nejmra1703481 · Cited by 4,849 · see citing works

Chimeric antigen receptor–modified T cells in chronic lymphoid leukemia

Porter, D. L., Levine, B. L., Kalos, M., Bagg, A., & June, C. H. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103849 · Cited by 3,565 · see citing works

Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia

Grupp, S. A., Kalos, M., Barrett, D., Aplenc, R., Porter, D. L., Rheingold, S. R., Teachey, D. T., Chew, A., Hauck, B., Wright, J. F., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215134 · Cited by 3,509 · see citing works

Cancer regression in patients after transfer of genetically engineered lymphocytes

Morgan, R. A., Dudley, M. E., Wunderlich, J. R., Hughes, M. S., Yang, J. C., Sherry, R. M., Royal, R. E., Topalian, S. L., Kammula, U. S., Restifo, N. P., et al. (2006) · Science · doi:10.1126/science.1129003 · Cited by 2,603 · see citing works

Case Report of a Serious Adverse Event Following the Administration of T Cells Transduced With a Chimeric Antigen Receptor Recognizing ERBB2

Morgan, R. A., Yang, J. C.-H., Kitano, M., Dudley, M. E., Laurençot, C. M., & Rosenberg, S. A. (2010) · Molecular Therapy · doi:10.1038/mt.2010.24 · Cited by 2,542 · see citing works

T cell exclusion, immune privilege, and the tumor microenvironment

Joyce, J. A., & Fearon, D. T. (2015) · Science · doi:10.1126/science.aaa6204 · Cited by 2,494 · see citing works

Adoptive cell transfer as personalized immunotherapy for human cancer

Rosenberg, S. A., & Restifo, N. P. (2015) · Science · doi:10.1126/science.aaa4967 · Cited by 2,492 · see citing works

T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia

Kalos, M. D., Levine, B. L., Porter, D. L., Katz, S. I., Grupp, S. A., Bagg, A., & June, C. H. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002842 · Cited by 2,389 · see citing works

CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia

Brentjens, R. J., Davila, M. L., Riviere, I., Park, J., Wang, X., Cowell, L. G., Bartido, S., Stefanski, J., Taylor, C., Olszewska, M., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3005930 · Cited by 2,063 · see citing works

Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy

Brown, C. E., Alizadeh, D., Starr, R., Weng, L., Wagner, J. R., Naranjo, A., Ostberg, J. R., Blanchard, M. S., Kilpatrick, J., Simpson, J., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1610497 · Cited by 1,842 · see citing works

Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection

Eyquem, J., Mansilla-Soto, J., Giavridis, T., van der Stegen, S. J. C., Hamieh, M., Cunanan, K. M., Odak, A., Gönen, M., & Sadelain, M. (2017) · Nature · doi:10.1038/nature21405 · Cited by 1,831 · see citing works

A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma

O’Rourke, D. M., Nasrallah, M. P., Desai, A. S., Melenhorst, J. J., Mansfield, K. G., Morrissette, J. J. D., Martinez‐Lage, M., Brem, S. S., Maloney, E., Shen, A., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aaa0984 · Cited by 1,812 · see citing works

Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia

Porter, D. L., Hwang, W.-T., Frey, N. V., Lacey, S. F., Shaw, P. A., Loren, A. W., Bagg, A., Marcucci, K. T., Shen, A., Gonzalez, V., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aac5415 · Cited by 1,729 · see citing works

Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity.

Gross, G., Waks, T., & Eshhar, Z. (1989) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.86.24.10024 · Cited by 1,597 · see citing works

Inducible Apoptosis as a Safety Switch for Adoptive Cell Therapy

Di Stasi, A., Tey, S.-K., Dotti, G., Fujita, Y., Kennedy-Nasser, A., Martinez, C., Straathof, K., Liu, E., Durett, A. G., Grilley, B., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1106152 · Cited by 1,512 · see citing works

B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor–transduced T cells

Kochenderfer, J. N., Dudley, M. E., Feldman, S. A., Wilson, W. H., Spaner, D., Marić, I., Stetler‐Stevenson, M., Phan, G. Q., Hughes, M. S., Sherry, R. M., et al. (2011) · Blood · doi:10.1182/blood-2011-10-384388 · Cited by 1,441 · see citing works

Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen

Johnson, L. A., Morgan, R. A., Dudley, M. E., Cassard, L., Yang, J. C.-H., Hughes, M. S., Kammula, U. S., Royal, R. E., Sherry, R. M., Wunderlich, J. R., et al. (2009) · Blood · doi:10.1182/blood-2009-03-211714 · Cited by 1,421 · see citing works

Endothelial Activation and Blood–Brain Barrier Disruption in Neurotoxicity after Adoptive Immunotherapy with CD19 CAR-T Cells

Gust, J., Hay, K. A., Hanafi, L.-A., Li, D., Myerson, D., Gonzalez-Cuyar, L. F., Yeung, C., Liles, W. C., Wurfel, M., Lopez, J. A., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0698 · Cited by 1,400 · see citing works

Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19

Kochenderfer, J. N., Wilson, W. H., Janik, J. E., Dudley, M. E., Stetler-Stevenson, M., Feldman, S. A., Maric, I., Raffeld, M., Nathan, D.-A. N., Lanier, B. J., et al. (2010) · Blood · doi:10.1182/blood-2010-04-281931 · Cited by 1,337 · see citing works

CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy

Fry, T. J., Shah, N. N., Orentas, R. J., Stetler‐Stevenson, M., Yuan, C. M., Ramakrishna, S., Wolters, P. L., Martin, S. C., Delbrook, C., Yates, B., et al. (2017) · Nature Medicine · doi:10.1038/nm.4441 · Cited by 1,336 · see citing works

Convergence of Acquired Mutations and Alternative Splicing of CD19 Enables Resistance to CART-19 Immunotherapy

Sotillo, E., Barrett, D. M., Black, K. L., Bagashev, A., Oldridge, D. A., Wu, G. S., Sussman, R. T., Lanauze, C. B., Ruella, M., Gazzara, M. R., et al. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-1020 · Cited by 1,251 · see citing works

Chimeric Receptors Containing CD137 Signal Transduction Domains Mediate Enhanced Survival of T Cells and Increased Antileukemic Efficacy In Vivo

Milone, M. C., Fish, J. D., Carpenito, C., Carroll, R. G., Binder, G. K., Teachey, D., Samanta, M., Lakhal, M., Gloss, B., Danet-Desnoyers, G., et al. (2009) · Molecular Therapy · doi:10.1038/mt.2009.83 · Cited by 1,197 · see citing works

Cancer Regression and Neurological Toxicity Following Anti-MAGE-A3 TCR Gene Therapy

Morgan, R. A., Chinnasamy, N., Abate‐Daga, D., Gros, A., Robbins, P. F., Zheng, Z., Dudley, M. E., Feldman, S. A., Yang, J. C., Sherry, R. M., et al. (2013) · Journal of Immunotherapy · doi:10.1097/cji.0b013e3182829903 · Cited by 1,155 · see citing works

Identification of preexisting adaptive immunity to Cas9 proteins in humans

Charlesworth, C. T., Deshpande, P. S., Dever, D. P., Camarena, J., Lemgart, V. T., Cromer, M. K., Vakulskas, C. A., Collingwood, M. A., Zhang, L., Bode, N. M., et al. (2019) · Nature Medicine · doi:10.1038/s41591-018-0326-x · Cited by 1,093 · see citing works

The Principles of Engineering Immune Cells to Treat Cancer

Lim, W. A., & June, C. H. (2017) · Cell · doi:10.1016/j.cell.2017.01.016 · Cited by 1,084 · see citing works

Precision Tumor Recognition by T Cells With Combinatorial Antigen-Sensing Circuits

Roybal, K. T., Rupp, L. J., Morsut, L., Walker, W. J., McNally, K. A., Park, J. S., & Lim, W. A. (2016) · Cell · doi:10.1016/j.cell.2016.01.011 · Cited by 1,010 · see citing works

Human Epidermal Growth Factor Receptor 2 (HER2) –Specific Chimeric Antigen Receptor–Modified T Cells for the Immunotherapy of HER2-Positive Sarcoma

Ahmed, N., Brawley, V. S., Hegde, M., Robertson, C., Ghazi, A., Gerken, C., Liu, E., Dakhova, O., Ashoori, A., Corder, A., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.58.0225 · Cited by 1,004 · see citing works

LIGAND RECOGNITION BY αβ T CELL RECEPTORS

Davis, M. M., Boniface, J. J., Reich, Z., Lyons, D. S., Hampl, J., Arden, B., & Chien, Y. (1998) · Annual Review of Immunology · doi:10.1146/annurev.immunol.16.1.523 · Cited by 924 · see citing works

Molecular remission of infant B-ALL after infusion of universal TALEN gene-edited CAR T cells

Qasim, W., Zhan, H., Samarasinghe, S., Adams, S., Amrolia, P., Stafford, S., Butler, K., Rivat, C., Wright, G., Somana, K., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aaj2013 · Cited by 902 · see citing works

Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells

Kloss, C. C., Condomines, M., Cartellieri, M., Bachmann, M. P., & Sadelain, M. (2012) · Nature Biotechnology · doi:10.1038/nbt.2459 · Cited by 860 · see citing works

NY-ESO-1–specific TCR–engineered T cells mediate sustained antigen-specific antitumor effects in myeloma

Rapoport, A. P., Stadtmauer, E. A., Binder-Scholl, G. K., Goloubeva, O. G., Vogl, D. T., Lacey, S. F., Badros, A. Z., Garfall, A. L., Weiss, B. M., Finklestein, J. M., et al. (2015) · Nature Medicine · doi:10.1038/nm.3910 · Cited by 857 · see citing works

T cells expressing an anti–B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma

Ali, S. A., Shi, V., Marić, I., Wang, M. L., Stroncek, D. F., Rose, J. J., Brudno, J. N., Stetler‐Stevenson, M., Feldman, S. A., Hansen, B. G., et al. (2016) · Blood · doi:10.1182/blood-2016-04-711903 · Cited by 759 · see citing works

Treatment of Metastatic Renal Cell Carcinoma With CAIX CAR-engineered T cells: Clinical Evaluation and Management of On-target Toxicity

Lamers, C. H., Sleijfer, S., van Steenbergen, S. C. L., van Elzakker, P., Krimpen, B. A. V., Groot, C., Vulto, A. G., den Bakker, M., Oosterwijk, E., Debets, R., et al. (2013) · Molecular Therapy · doi:10.1038/mt.2013.17 · Cited by 706 · see citing works

Identification of a Titin-Derived HLA-A1–Presented Peptide as a Cross-Reactive Target for Engineered MAGE A3–Directed T Cells

Cameron, B., Gerry, A. B., Dukes, J. D., Harper, J. V., Kannan, V., Bianchi, F., Grand, F., Brewer, J. E., Gupta, M., Plesa, G., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3006034 · Cited by 685 · see citing works

Decade-Long Safety and Function of Retroviral-Modified Chimeric Antigen Receptor T Cells

Scholler, J., Brady, T., Binder-Scholl, G. K., Hwang, W., Plesa, G., Hege, K. M., Vogel, A. N., Kalos, M. D., Riley, J. L., Deeks, S. G., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003761 · Cited by 651 · see citing works

HLA-E-expressing pluripotent stem cells escape allogeneic responses and lysis by NK cells

Gornalusse, G. G., Hirata, R. K., Funk, S. E., Riolobos, L., Lopes, V. S., Manske, G., Prunkard, D., Colunga, A. G., Hanafi, L.-A., Clegg, D. O., et al. (2017) · Nature Biotechnology · doi:10.1038/nbt.3860 · Cited by 639 · see citing works

Chimeric Antigen Receptor T Cells against CD19 for Multiple Myeloma

Garfall, A. L., Maus, M. V., Hwang, W.-T., Lacey, S. F., Mahnke, Y. D., Melenhorst, J. J., Zheng, Z., Vogl, D. T., Cohen, A. D., Weiss, B. M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504542 · Cited by 624 · see citing works

The urgent need to recover MHC class I in cancers for effective immunotherapy

Garrido, F., Aptsiauri, N., Doorduijn, E. M., Garcia Lora, A. M., & van Hall, T. (2016) · Current Opinion in Immunology · doi:10.1016/j.coi.2015.12.007 · Cited by 585 · see citing works

An Antibody-Deficiency Syndrome Due to Mutations in theCD19Gene

van Zelm, M. C., Reisli, İ., van der Burg, M., Castaño, D., van Noesel, C. J. M., van Tol, M. J. D., Woellner, C., Grimbacher, B., Grajales, P. J. P., van Dongen, J. J. M., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa051568 · Cited by 536 · see citing works

A foundation for universal T-cell based immunotherapy: T cells engineered to express a CD19-specific chimeric-antigen-receptor and eliminate expression of endogenous TCR.

Torikai, H., Reik, A., Liu, P.-Q., Zhou, Y.-Y., Zhang, L., Maiti, S., Huls, H., Miller, J. C., Kebriaei, P., Rabinovitch, B., et al. (2012) · Blood · doi:10.1182/blood-2012-01-405365 · Cited by 522 · see citing works

Engineering CAR-T cells: Design concepts

Srivastava, S., & Riddell, S. R. (2015) · Trends in Immunology · doi:10.1016/j.it.2015.06.004 · Cited by 489 · see citing works

Neoantigen landscape dynamics during human melanoma–T cell interactions

Verdegaal, E. M. E., de Miranda, N. F. C. C., Visser, M., Harryvan, T. J., van Buuren, M. M., Andersen, R. S., Hadrup, S. R., van der Minne, C. E., Schotte, R., Spits, H., et al. (2016) · Nature · doi:10.1038/nature18945 · Cited by 464 · see citing works

Is autoimmunity the Achilles' heel of cancer immunotherapy?

June, C. H., Warshauer, J. T., & Bluestone, J. A. (2017) · Nature Medicine · doi:10.1038/nm.4321 · Cited by 445 · see citing works

Expression of chimeric receptor composed of immunoglobulin-derived V resions and T-cell receptor-derived C regions

Kuwana, Y., Asakura, Y., Utsunomiya, N., Nakanishi, M., Arata, Y., Itoh, S., Nagase, F., & Kurosawa, Y. (1987) · Biochemical and Biophysical Research Communications · doi:10.1016/0006-291x(87)90502-x · Cited by 432 · see citing works

The clinical efficacy of first-generation carcinoembryonic antigen (CEACAM5)-specific CAR T cells is limited by poor persistence and transient pre-conditioning-dependent respiratory toxicity

Thistlethwaite, F. C., Gilham, D. E., Guest, R. D., Rothwell, D. G., Pillai, M. R., Burt, D. J., Byatte, A. J., Kirillova, N., Valle, J. W., Sharma, S. K., et al. (2017) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-017-2034-7 · Cited by 408 · see citing works

Adoptive cellular therapy: A race to the finish line

June, C. H., Riddell, S. R., & Schumacher, T. N. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aaa3643 · Cited by 402 · see citing works

Tuning Sensitivity of CAR to EGFR Density Limits Recognition of Normal Tissue While Maintaining Potent Antitumor Activity

Caruso, H. G., Hurton, L. V., Najjar, A. M., Rushworth, D., Ang, S., Olivares, S., Mi, T., Switzer, K. C., Singh, H., Huls, H. M., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-15-0139 · Cited by 399 · see citing works

Phase 1 studies of central memory–derived CD19 CAR T–cell therapy following autologous HSCT in patients with B-cell NHL

Wang, X., Popplewell, L. L., Wagner, J. R., Naranjo, A., Blanchard, M. S., Mott, M., Norris, A. P., Wong, C. W., Urak, R. Z., Chang, W.-C., et al. (2016) · Blood · doi:10.1182/blood-2015-12-686725 · Cited by 323 · see citing works

Effects of antenatal diet and physical activity on maternal and fetal outcomes: individual patient data meta-analysis and health economic evaluation

Rogozińska, E., Marlin, N., Jackson, L., Rayanagoudar, G., Ruifrok, A. E., Dodds, J. P., Molyneaux, E., van Poppel, M. N. M., Poston, L., Vinter, C. A., et al. (2017) · Health Technology Assessment · doi:10.3310/hta21410 · Cited by 299 · see citing works

Persistence of long-lived plasma cells and humoral immunity in individuals responding to CD19-directed CAR T-cell therapy

Bhoj, V. G., Arhontoulis, D. C., Wertheim, G. B. W., Capobianchi, J., Callahan, C. A., Ellebrecht, C. T., Obstfeld, A. E., Lacey, S. F., Melenhorst, J. J., Nazimuddin, F., et al. (2016) · Blood · doi:10.1182/blood-2016-01-694356 · Cited by 278 · see citing works

High-Affinity GD2-Specific CAR T Cells Induce Fatal Encephalitis in a Preclinical Neuroblastoma Model

Richman, S. A., Nuñez-Cruz, S., Moghimi, B., Li, L. Z., Gershenson, Z. T., Mourelatos, Z., Barrett, D. M., Grupp, S. A., & Milone, M. C. (2017) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-17-0211 · Cited by 269 · see citing works

Different affinity windows for virus and cancer‐specific T ‐cell receptors: Implications for therapeutic strategies

Aleksic, M., Liddy, N., Molloy, P. E., Pumphrey, N. J., Vuidepot, A., Chang, K., & Jakobsen, B. K. (2012) · European Journal of Immunology · doi:10.1002/eji.201242606 · Cited by 250 · see citing works

Fully human CD19-specific chimeric antigen receptors for T-cell therapy

Sommermeyer, D., Hill, T. J., Shamah, S. M., Salter, A. I., Chen, Y., Mohler, K., & Riddell, S. R. (2017) · Leukemia · doi:10.1038/leu.2017.57 · Cited by 221 · see citing works

Identification of Pre-Existing Adaptive Immunity to Cas9 Proteins in HumansPreprint

Charlesworth, C. T., Deshpande, P. S., Dever, D. P., et al. (2018) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/243345 · Cited by 185 · see citing works

Economic Burden of Chronic Lymphocytic Leukemia in the Era of Oral Targeted Therapies in the United States

Chen, Q., Jain, N., Ayer, T., Wierda, W. G., Flowers, C. R., O'Brien, S. M., Keating, M. J., Kantarjian, H. M., & Chhatwal, J. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.68.2856 · Cited by 168 · see citing works

CAR-T Cells Inflict Sequential Killing of Multiple Tumor Target Cells

Davenport, A. J., Jenkins, M. R., Cross, R. S., Yong, C. S. M., Prince, H. M., Ritchie, D. S., Trapani, J. A., Kershaw, M. H., Darcy, P. K., & Neeson, P. J. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0048 · Cited by 157 · see citing works

Measuring the Value of Prescription Drugs

Neumann, P. J., & Cohen, J. T. (2015) · New England Journal of Medicine · doi:10.1056/nejmp1512009 · Cited by 145 · see citing works

Toxicity management for patients receiving novel T-cell engaging therapies

Barrett, D. M., Teachey, D. T., & Grupp, S. A. (2013) · Current Opinion in Pediatrics · doi:10.1097/mop.0000000000000043 · Cited by 143 · see citing works

T cell receptor binding affinity governs the functional profile of cancer-specific CD8+ T cells

Tan, M. P., Gerry, A. B., Brewer, J., Melchiori, L., Bridgeman, J. S., Bennett, A., Pumphrey, N. J., Jakobsen, B. K., Price, D. A., Ladell, K., et al. (2014) · Clinical & Experimental Immunology · doi:10.1111/cei.12570 · Cited by 135 · see citing works

The assessment and appraisal of regenerative medicines and cell therapy products: an exploration of methods for review, economic evaluation and appraisal

Hettle, R., Corbett, M. S., Hinde, S., Hodgson, R. M., Jones-Diette, J. S., Woolacott, N. F., & Palmer, S. (2017) · Health Technology Assessment · doi:10.3310/hta21070 · Cited by 126 · see citing works

Tumor immunotherapy across MHC barriers using allogeneic T-cell precursors

Zakrzewski, J. L., Suh, D. Y., Markley, J. C., Smith, O. M., King, C. G., Goldberg, G. L., Jenq, R. R., Holland, A. M., Grubin, J., Cabrera-Pérez, J., et al. (2008) · Nature Biotechnology · doi:10.1038/nbt1395 · Cited by 119 · see citing works

A sensitivity scale for targeting T cells with chimeric antigen receptors (CARs) and bispecific T-cell Engagers (BiTEs)

Stone, J. D., Aggen, D. H., Schietinger, A., Schreiber, H. W., & Kranz, D. M. (2012) · OncoImmunology · doi:10.4161/onci.20592 · Cited by 92 · see citing works

Perspective: Assembly line immunotherapy

Levine, B. L., & June, C. H. (2013) · Nature · doi:10.1038/498s17a · Cited by 41 · see citing works

Palindromic amplification of the ERBB2 oncogene in primary HER2-positive breast tumors

Marotta, M. L., Onodera, T., Johnson, J. E., Budd, G. T., Watanabe, T., Cui, X., Giuliano, A. E., Niida, A., & Tanaka, H. (2017) · Scientific Reports · doi:10.1038/srep41921 · Cited by 38 · see citing works

Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people: systematic review and economic evaluation

Duarte, A., Mebrahtu, T. F., Saramago, P., Harden, M., Murphy, R., Palmer, S., Woolacott, N. F., Rodgers, M., & Rothery, C. (2017) · Health Technology Assessment · doi:10.3310/hta21640 · Cited by 30 · see citing works

Bypassing the Constraint for Chimeric Antigen Receptor (CAR) Development in T-Cells Expressing the Targeted Antigen: Improvement of Anti-CS1 CAR Activity in Allogenic TCRa/CS1 Double Knockout T-Cells for the Treatment of Multiple Myeloma (MM)

Galetto, R., Chion-Sotinel, I., Gouble, A., & Smith, J. (2015) · Blood · doi:10.1182/blood.v126.23.116.116 · Cited by 12 · see citing works

CAR-T cell therapy: current limitations and potential strategies

Sterner, R. C., & Sterner, R. M. (2021) · Blood Cancer Journal · doi:10.1038/s41408-021-00459-7 · Cited by 2,926 · see citing works

Photothermal therapy and photoacoustic imaging via nanotheranostics in fighting cancer

Liu, Y., Bhattarai, P., Dai, Z., & Chen, X. S. (2018) · Chemical Society Reviews · doi:10.1039/c8cs00618k · Cited by 2,918 · see citing works

Delivery technologies for cancer immunotherapy

Riley, R., June, C. H., Langer, R., & Mitchell, M. J. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-018-0006-z · Cited by 2,621 · see citing works

Chimeric Antigen Receptor Therapy

June, C. H., & Sadelain, M. (2018) · New England Journal of Medicine · doi:10.1056/nejmra1706169 · Cited by 2,351 · see citing works

Top 10 Challenges in Cancer Immunotherapy

Hegde, P. S., & Chen, D. S. (2020) · Immunity · doi:10.1016/j.immuni.2019.12.011 · Cited by 2,238 · see citing works

Development of therapeutic antibodies for the treatment of diseases

Lu, R., Hwang, Y., Liu, I.-J., Lee, C., Tsai, H.-Z., Li, H., & Wu, H. (2020) · Journal of Biomedical Science · doi:10.1186/s12929-019-0592-z · Cited by 2,106 · see citing works

IL-6 in inflammation, autoimmunity and cancer

Hirano, T. (2021) · International Immunology · doi:10.1093/intimm/dxaa078 · Cited by 1,453 · see citing works

The evolution of commercial drug delivery technologies

Vargason, A. M., Anselmo, A. C., & Mitragotri, S. (2021) · Nature Biomedical Engineering · doi:10.1038/s41551-021-00698-w · Cited by 1,361 · see citing works

The current landscape of nucleic acid therapeutics

Kulkarni, J. A., Witzigmann, D., Thomson, S. B., Chen, S., Leavitt, B. R., Cullis, P. R., & van der Meel, R. (2021) · Nature Nanotechnology · doi:10.1038/s41565-021-00898-0 · Cited by 1,371 · see citing works

Smart cancer nanomedicine

van der Meel, R., Sulheim, E., Shi, Y., Kiessling, F. M., Mulder, W. J. M., & Lammers, T. (2019) · Nature Nanotechnology · doi:10.1038/s41565-019-0567-y · Cited by 1,251 · see citing works

‘Off-the-shelf’ allogeneic CAR T cells: development and challenges

Depil, S., Duchateau, P. N., Grupp, S. A., Mufti, G. J., & Poirot, L. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0051-2 · Cited by 1,236 · see citing works

Cytokines in clinical cancer immunotherapy

Berraondo, P., Sanmamed, M. F., Ochoa, M. C., Etxeberría, I., Aznar, M. A., Perez‐Gracia, J. L., Rodriguez-Ruiz, M. E., Ponz‐Sarvisé, M., Álvarez, E. C., & Melero, I. (2018) · British Journal of Cancer · doi:10.1038/s41416-018-0328-y · Cited by 1,190 · see citing works

A Patient-Derived Glioblastoma Organoid Model and Biobank Recapitulates Inter- and Intra-tumoral Heterogeneity

Jacob, F., Salinas, R. D., Zhang, D. Y., Nguyen, P. T. T., Schnoll, J. G., Wong, S. Z. H., Thokala, R., Sheikh, S., Saxena, D., Prokop, S., et al. (2020) · Cell · doi:10.1016/j.cell.2019.11.036 · Cited by 1,149 · see citing works

CD19 CAR T-Cell Therapy in Autoimmune Disease - A Case Series with Follow-up.

Müller, F., Taubmann, J., Bucci, L., Wilhelm, A., Bergmann, C., Völkl, S., Aigner, M., Rothe, T., Minopoulou, I., Tur, C., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2308917 · Cited by 856 · see citing works

Targeting STAT3 in Cancer Immunotherapy

Zou, S., Tong, Q., Liu, B., Huang, W., Tian, Y., & Fu, X. (2020) · Molecular Cancer · doi:10.1186/s12943-020-01258-7 · Cited by 1,075 · see citing works

Guidelines for the use of flow cytometry and cell sorting in immunological studies (second edition)

Cossarizza, A., Chang, H., Radbruch, A., Acs, A., Adam, D., Adam‐Klages, S., Agace, W. W., Aghaeepour, N., Akdiş, M., Allez, M., et al. (2019) · European Journal of Immunology · doi:10.1002/eji.201970107 · Cited by 982 · see citing works

Biopharmaceutical benchmarks 2018

Walsh, G. (2018) · Nature Biotechnology · doi:10.1038/nbt.4305 · Cited by 978 · see citing works

Harnessing innate immunity in cancer therapy

Demaria, O., Cornen, S., Daëron, M., Morel, Y., Medzhitov, R., & Vivier, E. (2019) · Nature · doi:10.1038/s41586-019-1593-5 · Cited by 957 · see citing works

Mechanisms of resistance to CAR T cell therapy

Shah, N. N., & Fry, T. J. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0184-6 · Cited by 984 · see citing works

c-Jun overexpression in CAR T cells induces exhaustion resistance

Lynn, R. C., Weber, E. W., Sotillo, E., Gennert, D., Xu, P., Good, Z., Anbunathan, H., Lattin, J., Jones, R., Tieu, V., et al. (2019) · Nature · doi:10.1038/s41586-019-1805-z · Cited by 891 · see citing works

Enhancing cancer immunotherapy with nanomedicine

Irvine, D. J., & Dane, E. L. (2020) · Nature reviews. Immunology · doi:10.1038/s41577-019-0269-6 · Cited by 900 · see citing works

Tumor-infiltrating lymphocytes in the immunotherapy era

Paijens, S. T., Vledder, A., de Bruyn, M., & Nijman, H. W. (2020) · Cellular and Molecular Immunology · doi:10.1038/s41423-020-00565-9 · Cited by 887 · see citing works

CAR T Cells for Solid Tumors: New Strategies for Finding, Infiltrating, and Surviving in the Tumor Microenvironment

Martinez, M. C., & Moon, E. K. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00128 · Cited by 855 · see citing works

Targeting cardiac fibrosis with engineered T cells

Aghajanian, H., Kimura, T., Rurik, J. G., Hancock, A. S., Leibowitz, M. S., Li, L., Scholler, J., Monslow, J., Lo, A., Han, W., et al. (2019) · Nature · doi:10.1038/s41586-019-1546-z · Cited by 801 · see citing works

Turning cold tumors into hot tumors by improving T-cell infiltration

Liu, Y., & Sun, Z. (2021) · Theranostics · doi:10.7150/thno.58390 · Cited by 836 · see citing works

TOX and TOX2 transcription factors cooperate with NR4A transcription factors to impose CD8 ⁺ T cell exhaustion

Seo, H., Chen, J., González-Avalos, E., Samaniego-Castruita, D., Das, A., Wang, Y. H., López-Moyado, I. F., Georges, R. O., Zhang, W., Onodera, A., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1905675116 · Cited by 808 · see citing works

Natural killer cells in antitumour adoptive cell immunotherapy

Laskowski, T. J., Biederstadt, A., & Rezvani, K. (2022) · Nature Reviews. Cancer · doi:10.1038/s41568-022-00491-0 · Cited by 680 · see citing works

The future of cancer immunotherapy: microenvironment-targeting combinations

Murciano‐Goroff, Y. R., Warner, A. B., & Wolchok, J. D. (2020) · Cell Research · doi:10.1038/s41422-020-0337-2 · Cited by 753 · see citing works

Challenges and Opportunities for Pancreatic Cancer Immunotherapy

Bear, A. S., Vonderheide, R. H., & O'Hara, M. H. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.08.004 · Cited by 674 · see citing works

Combination strategies to maximize the benefits of cancer immunotherapy

Zhu, S., Zhang, T., Zheng, L., Liu, H., Song, W., Liu, D., Li, Z., & Pan, C.-X. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01164-5 · Cited by 654 · see citing works

T cell-engaging therapies — BiTEs and beyond

Goebeler, M.-E., & Bargou, R. C. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0347-5 · Cited by 653 · see citing works

CAR-cell therapy in the era of solid tumor treatment: current challenges and emerging therapeutic advances

Makni‐Maalej, K., Merhi, M., Inchakalody, V. P., Mestiri, S., Alam, M. A., Maccalli, C., Cherif, H., Shahab Uddin, M. S., Steinhoff, M. S., Marincola, F. M., et al. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01723-z · Cited by 638 · see citing works

Tumor microenvironment: Challenges and opportunities in targeting metastasis of triple negative breast cancer

Deepak, K. G. K., Vempati, R. K., Nagaraju, G. P., Dasari, V. R., Nagini, S., Rao, D. N., & Malla, R. R. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.104683 · Cited by 618 · see citing works

Past, present, and future of CRISPR genome editing technologies

Pacesa, M., Pelea, O., & Jinek, M. (2024) · Cell · doi:10.1016/j.cell.2024.01.042 · Cited by 609 · see citing works

The hallmarks of successful anticancer immunotherapy

Galluzzi, L., Chan, T. A., Kroemer, G., Wolchok, J. D., & López-Soto, A. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aat7807 · Cited by 575 · see citing works

Combination Immunotherapy with CAR T Cells and Checkpoint Blockade for the Treatment of Solid Tumors

Grosser, R., Cherkassky, L., Chintala, N., & Adusumilli, P. S. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.09.006 · Cited by 603 · see citing works

Overcoming tumor hypoxia as a barrier to radiotherapy, chemotherapy and immunotherapy in cancer treatment

Graham, K., & Unger, E. C. (2018) · International Journal of Nanomedicine · doi:10.2147/ijn.s140462 · Cited by 581 · see citing works

Cancer stemness, intratumoral heterogeneity, and immune response across cancers

Miranda, A., Hamilton, P. T., Zhang, A. W., Pattnaik, S., Becht, É., Mezheyeuski, A., Bruun, J., Micke, P., de Reyniès, A., & Nelson, B. H. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1818210116 · Cited by 580 · see citing works

Genome-wide CRISPR Screens in Primary Human T Cells Reveal Key Regulators of Immune Function

Shifrut, E., Carnevale, J., Tobin, V., Roth, T. L., Woo, J. M., Bui, C. T., Li, P. J., Diolaiti, M. E., Ashworth, A., & Marson, A. (2018) · Cell · doi:10.1016/j.cell.2018.10.024 · Cited by 573 · see citing works

Cancer stem cells: advances in knowledge and implications for cancer therapy

Chu, X., Tian, W., Ning, J., Xiao, G., Zhou, Y., Wang, Z., Zhai, Z., Tanzhu, G., Yang, J., & Zhou, R. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01851-y · Cited by 597 · see citing works

Optimizing oncolytic virotherapy in cancer treatment

Harrington, K. J., Freeman, D. J., Kelly, E. J., Harper, J. A., & Soria, J. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0029-0 · Cited by 523 · see citing works

An RNA vaccine drives expansion and efficacy of claudin-CAR-T cells against solid tumors

Reinhard, K., Rengstl, B., Oehm, P., Michel, K., Billmeier, A., Hayduk, N., Klein, O., Kuna, K., Ouchan, Y., Wöll, S., et al. (2020) · Science · doi:10.1126/science.aay5967 · Cited by 512 · see citing works

Emerging therapies for glioblastoma: current state and future directions

Rong, L., Li, N., & Zhang, Z. (2022) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-022-02349-7 · Cited by 512 · see citing works

Intratumoural administration and tumour tissue targeting of cancer immunotherapies

Melero, I., Álvarez, E. C., Álvarez, M., Champiat, S., & Marabelle, A. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00507-y · Cited by 492 · see citing works

Base editing: advances and therapeutic opportunities

Porto, E. M., Komor, A. C., Slaymaker, I. M., & Yeo, G. W.-M. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0084-6 · Cited by 475 · see citing works

Emerging new therapeutic antibody derivatives for cancer treatment

Jin, S., Sun, Y., Xiao, L., Gu, X., Ning, J., Xu, Y., Chen, S., & Pan, L. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00868-x · Cited by 461 · see citing works

Single-Cell Analyses Identify Brain Mural Cells Expressing CD19 as Potential Off-Tumor Targets for CAR-T Immunotherapies

Parker, K. R., Migliorini, D., Perkey, E., Yost, K. E., Bhaduri, A., Bagga, P., Haris, M., Wilson, N. E., Liu, F., Gabunia, K., et al. (2020) · Cell · doi:10.1016/j.cell.2020.08.022 · Cited by 451 · see citing works

Advances in acute myeloid leukemia

Newell, L. F., & Cook, R. J. (2021) · BMJ · doi:10.1136/bmj.n2026 · Cited by 455 · see citing works

Metabolic reprogramming of terminally exhausted CD8+ T cells by IL-10 enhances anti-tumor immunity

Guo, Y., Xie, Y., Gao, M., Zhao, Y., Franco, F., Wenes, M., Siddiqui, I., Bevilacqua, A., Wang, H., Yang, H., et al. (2021) · Nature Immunology · doi:10.1038/s41590-021-00940-2 · Cited by 441 · see citing works

Multifunctional Natural Killer Cell Engagers Targeting NKp46 Trigger Protective Tumor Immunity

Gauthier, L., Morel, A., Anceriz, N., Rossi, B., Blanchard-Alvarez, A., Grondin, G., Trichard, S., Cesari, C., Sapet, M., Bosco, F., et al. (2019) · Cell · doi:10.1016/j.cell.2019.04.041 · Cited by 444 · see citing works

Engineering the next generation of cell-based therapeutics

Bashor, C. J., Hilton, I. B., Bandukwala, H. S., Smith, D. M., & Omid Veiseh, A. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00476-6 · Cited by 448 · see citing works

Enhanced CAR–T cell activity against solid tumors by vaccine boosting through the chimeric receptor

Ma, L., Dichwalkar, T., Chang, J. Y. H., Cossette, B. J., Garafola, D., Zhang, A. Q., Fichter, M., Wang, C., Liang, S., Silva, M., et al. (2019) · Science · doi:10.1126/science.aav8692 · Cited by 439 · see citing works

Supramolecular cancer nanotheranostics

Zhou, J., Rao, L., Yu, G., Cook, T. R., Chen, X., & Huang, F. (2021) · Chemical Society Reviews · doi:10.1039/d0cs00011f · Cited by 411 · see citing works

Paradigms on Immunotherapy Combinations with Chemotherapy

Salas‐Benito, D., Perez‐Gracia, J. L., Ponz‐Sarvisé, M., Rodriguez-Ruiz, M. E., Martínez‐Forero, I., Álvarez, E. C., López-Picazo, J. M., Sanmamed, M. F., & Melero, I. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1312 · Cited by 401 · see citing works

Recent advances in nanomaterial-based synergistic combination cancer immunotherapy

Sang, W., Zhang, Z., Dai, Y., & Chen, X. S. (2019) · Chemical Society Reviews · doi:10.1039/c8cs00896e · Cited by 408 · see citing works

Adoptive cellular therapies: the current landscape

Rohaan, M. W., Wilgenhof, S., & Haanen, J. B. A. G. (2018) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-018-2484-0 · Cited by 400 · see citing works

Exploratory trial of a biepitopic CAR T-targeting B cell maturation antigen in relapsed/refractory multiple myeloma

Xu, J., Chen, L., Yang, S., Sun, Y., Wu, W., Liu, Y., Xu, J., Zhuang, Y., Zhang, W., Weng, X., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1819745116 · Cited by 391 · see citing works

γδ T cells: origin and fate, subsets, diseases and immunotherapy

Hu, Y., Hu, Q., Li, Y., Lu, L., Xiang, Z., Yin, Z., Kabelitz, D., & Wu, Y. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01653-8 · Cited by 394 · see citing works

CAR-T and CAR-NK as cellular cancer immunotherapy for solid tumors

Peng, L., Sferruzza, G., Yang, L., Zhou, L., & Chen, S. (2024) · Cellular and Molecular Immunology · doi:10.1038/s41423-024-01207-0 · Cited by 414 · see citing works

Chimeric antigen receptor natural killer (CAR-NK) cell design and engineering for cancer therapy

Gong, Y., Klein Wolterink, R. G. J., Wang, J., Bos, G. M. J., & Germeraad, W. T. V. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01083-5 · Cited by 379 · see citing works

Non-viral, specifically targeted CAR-T cells achieve high safety and efficacy in B-NHL

Zhang, J., Hu, Y., Yang, J., Li, W., Zhang, M., Wang, Q., Zhang, L., Wei, G., Tian, Y., Zhao, K., et al. (2022) · Nature · doi:10.1038/s41586-022-05140-y · Cited by 380 · see citing works

NK cells switch from granzyme B to death receptor–mediated cytotoxicity during serial killing

Prager, I., Liesche, C., van Ooijen, H., Urlaub, D., Verron, Q., Sandström, N., Fasbender, F., Claus, M., Eils, R., Beaudouin, J., et al. (2019) · The Journal of Experimental Medicine · doi:10.1084/jem.20181454 · Cited by 376 · see citing works

<i>Enterococcus</i> peptidoglycan remodeling promotes checkpoint inhibitor cancer immunotherapy

Griffin, M. E., Espinosa, J., Becker, J. L., Luo, J.-D., Carroll, T. S., Jha, J. K., Fanger, G. R., & Hang, H. C. (2021) · Science · doi:10.1126/science.abc9113 · Cited by 366 · see citing works

Harnessing tumor‐associated macrophages as aids for cancer immunotherapy

Li, X., Liu, R., Su, X., Pan, Y., Han, X., Shao, C., & Shi, Y. (2019) · Molecular Cancer · doi:10.1186/s12943-019-1102-3 · Cited by 364 · see citing works

Cardiac fibrosis: Myofibroblast-mediated pathological regulation and drug delivery strategies

Liu, M., Abad, B. L. D. J., & Cheng, K. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.03.021 · Cited by 353 · see citing works

Structural basis of assembly of the human T cell receptor–CD3 complex

Dong, D., Zheng, L., Lin, J., Zhang, B., Zhu, Y., Li, N., Xie, S., Wang, Y., Gao, N., & Huang, Z. (2019) · Nature · doi:10.1038/s41586-019-1537-0 · Cited by 351 · see citing works

TCR-engineered T cells targeting E7 for patients with metastatic HPV-associated epithelial cancers

Nagarsheth, N., Norberg, S. M., Sinkoe, A. L., Adhikary, S., Meyer, T. J., Lack, J., Warner, A., Schweitzer, C., Doran, S. L., Korrapati, S., et al. (2021) · Nature Medicine · doi:10.1038/s41591-020-01225-1 · Cited by 349 · see citing works

Cancer-associated fibroblasts and their influence on tumor immunity and immunotherapy

Barrett, R. L., & Puré, E. (2020) · eLife · doi:10.7554/elife.57243 · Cited by 351 · see citing works

The approved gene therapy drugs worldwide: from 1998 to 2019

Ma, C., Wang, Z.-L., Xu, T., He, Z., & Wei, Y.-Q. (2019) · Biotechnology Advances · doi:10.1016/j.biotechadv.2019.107502 · Cited by 331 · see citing works

Biomolecular Condensates and Cancer

Boija, A., Klein, I. A., & Young, R. A. (2021) · Cancer Cell · doi:10.1016/j.ccell.2020.12.003 · Cited by 320 · see citing works

Biomimetic Nanotechnology toward Personalized Vaccines

Zhou, J., Kroll, A. V., Holay, M., Fang, R. H., & Zhang, L. (2019) · Advanced Materials · doi:10.1002/adma.201901255 · Cited by 333 · see citing works

Advances in PET imaging of cancer

Schwenck, J., Sonanini, D., Cotton, J. M., Rammensee, H., la Fougère, C., Zender, L., & Pichler, B. J. (2023) · Nature reviews. Cancer · doi:10.1038/s41568-023-00576-4 · Cited by 322 · see citing works

Time to abandon single-site irradiation for inducing abscopal effects

Brooks, E. D., & Chang, J. Y. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0119-7 · Cited by 312 · see citing works

CAR-T Cells Hit the Tumor Microenvironment: Strategies to Overcome Tumor Escape

Rodríguez-García, A., Palazón, A., Noguera-Ortega, E., Powell, D. J., & Guedan, S. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01109 · Cited by 317 · see citing works

Immunobiology and immunotherapy of HCC: spotlight on innate and innate-like immune cells

Ruf, B., Heinrich, B., & Greten, T. (2020) · Cellular & Molecular Immunology · doi:10.1038/s41423-020-00572-w · Cited by 282 · see citing works

Universal CARs, universal T cells, and universal CAR T cells

Zhao, J., Lin, Q., Song, Y., & Liu, D. (2018) · Journal of Hematology & Oncology · doi:10.1186/s13045-018-0677-2 · Cited by 315 · see citing works

Nanomaterials for T-cell cancer immunotherapy

Gong, N., Sheppard, N. C., Billingsley, M. M., June, C. H., & Mitchell, M. J. (2021) · Nature Nanotechnology · doi:10.1038/s41565-020-00822-y · Cited by 314 · see citing works

A second-generation M1-polarized CAR macrophage with antitumor efficacy

Lei, A., Yu, H., Lu, S., Lu, H., Ding, X., Tan, T., Zhang, H., Zhu, M., Tian, L., Wang, X., et al. (2023) · Nature Immunology · doi:10.1038/s41590-023-01687-8 · Cited by 312 · see citing works

Surgical Tumor-Derived Personalized Photothermal Vaccine Formulation for Cancer Immunotherapy

Ye, X., Liang, X., Chen, Q., Miao, Q., Chen, X., Zhang, X., & Mei, L. (2019) · ACS Nano · doi:10.1021/acsnano.8b07371 · Cited by 309 · see citing works

Nanoengineered Immune Niches for Reprogramming the Immunosuppressive Tumor Microenvironment and Enhancing Cancer Immunotherapy

Phuengkham, H., Ren, L. F., Shin, I. W., & Lim, Y. T. (2019) · Advanced Materials · doi:10.1002/adma.201803322 · Cited by 304 · see citing works

CAR T cells: Continuation in a revolution of immunotherapy

Singh, A. K., & McGuirk, J. P. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30823-x · Cited by 303 · see citing works

IL-7 and CCL19-secreting CAR-T cell therapy for tumors with positive glypican-3 or mesothelin

Pang, N., Shi, J., Qin, L., Chen, A., Tang, Y., Yang, H., Huang, Y., Wu, Q., Li, X., He, B., et al. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01128-9 · Cited by 303 · see citing works

CAR-T cell therapy for cancer: current challenges and future directions

Zugasti, I., Espinosa-Aroca, L., Fidyt, K., Mulens‐Arias, V., Díaz‐Beyá, M., Juan, M., Urbano-Ispizúa, Á., Esteve, J., Velasco-Hernández, T., & Menéndez, P. R. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02269-w · Cited by 332 · see citing works

Targeted and Immune-Based Therapies for Hepatocellular Carcinoma

Greten, T. F., Lai, C. W., Li, G., & Staveley-O’Carroll, K. F. (2018) · Gastroenterology · doi:10.1053/j.gastro.2018.09.051 · Cited by 293 · see citing works

Local biomaterials-assisted cancer immunotherapy to trigger systemic antitumor responses

Chen, Q., Chen, M., & Liu, Z. (2019) · Chemical Society Reviews · doi:10.1039/c9cs00271e · Cited by 289 · see citing works

The pre-existing T cell landscape determines the response to bispecific T cell engagers in multiple myeloma patients.

Friedrich, M., Neri, P., Kehl, N., Michel, J., Steiger, S., Kilian, M., Leblay, N., Maity, R., Sankowski, R., Lee, H., et al. (2023) · Cancer Cell · doi:10.1016/j.ccell.2023.02.008 · Cited by 233 · see citing works

Adverse Events Following Cancer Immunotherapy: Obstacles and Opportunities

Pauken, K. E., Dougan, M., Rose, N. R., Lichtman, A. H., & Sharpe, A. H. (2019) · Trends in Immunology · doi:10.1016/j.it.2019.04.002 · Cited by 280 · see citing works

Pluripotent stem cell–derived NK cells with high-affinity noncleavable CD16a mediate improved antitumor activity

Huang, Z., Blum, R. H., Bjordahl, R., Gaidarova, S., Rogers, P., Lee, T. T., Abujarour, R., Bonello, G. B., Wu, J., Tsai, P.-F., et al. (2019) · Blood · doi:10.1182/blood.2019000621 · Cited by 278 · see citing works

Smart Injectable Hydrogels for Cancer Immunotherapy

Chao, Y., Chen, Q., & Liu, Z. (2019) · Advanced Functional Materials · doi:10.1002/adfm.201902785 · Cited by 271 · see citing works

Effective combination immunotherapy using oncolytic viruses to deliver CAR targets to solid tumors

Park, A. K., Fong, Y., Kim, S., Yang, J., Murad, J. P., Lu, J., Jeang, B., Chang, W.-C., Chen, N. G., Thomas, S. H., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aaz1863 · Cited by 273 · see citing works

Immunotherapy for hepatocellular carcinoma

Zongyi, Y., & Li, X. (2019) · Cancer Letters · doi:10.1016/j.canlet.2019.12.002 · Cited by 266 · see citing works

Emerging Prospects of Exosomes for Cancer Treatment: From Conventional Therapy to Immunotherapy

Nam, G., Choi, Y., Kim, G. B., Kim, S., Kim, S. A., & Kim, I. (2020) · Advanced Materials · doi:10.1002/adma.202002440 · Cited by 266 · see citing works

Recent strategies for nano-based PTT combined with immunotherapy: from a biomaterial point of view

Huang, X., Lu, Y., Guo, M., Du, S., & Han, N. (2021) · Theranostics · doi:10.7150/thno.56482 · Cited by 267 · see citing works

Cytokines in CAR T Cell–Associated Neurotoxicity

Gust, J., Ponce, R. A., Liles, W. C., Garden, G. A., & Turtle, C. J. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.577027 · Cited by 268 · see citing works

Efficacy of adoptive therapy with tumor-infiltrating lymphocytes and recombinant interleukin-2 in advanced cutaneous melanoma: a systematic review and meta-analysis

Dafni, U., Michielin, O. A., Lluesma, S. M., Tsourti, Z., Polydoropoulou, V., Karlis, D., Besser, M. J., Haanen, J. B. A. G., Svane, I. M., Ohashi, P. S., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz398 · Cited by 264 · see citing works

Efficacy and safety of CAR19/22 T-cell cocktail therapy in patients with refractory/relapsed B-cell malignancies

Wang, N., Hu, X., Cao, W., Li, C., Xiao, Y., Cao, Y., Gu, C., Zhang, S., Chen, L., Cheng, J., et al. (2019) · Blood · doi:10.1182/blood.2019000017 · Cited by 264 · see citing works

Trispecific antibodies enhance the therapeutic efficacy of tumor-directed T cells through T cell receptor co-stimulation

Wu, L., Seung, E., Xu, L., Rao, E., Lord, D. M., Wei, R. R., Cortez‐Retamozo, V., Ospina, B., Posternak, V., Ulinski, G., et al. (2019) · Nature Cancer · doi:10.1038/s43018-019-0004-z · Cited by 263 · see citing works

Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non–Small Cell Lung Cancer

Yu, Y., Zeng, D., Ou, Q., Liu, S., Li, A., Chen, Y., Lin, D., Gao, Q., Zhou, H., Liao, W., et al. (2019) · JAMA Network Open · doi:10.1001/jamanetworkopen.2019.6879 · Cited by 261 · see citing works

Evolving understanding of autoimmune mechanisms and new therapeutic strategies of autoimmune disorders

Song, Y., Li, J., & Wu, Y. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01952-8 · Cited by 301 · see citing works

CAR-macrophage therapy for HER2-overexpressing advanced solid tumors: a phase 1 trial

Reiss, K. A., Angelos, M. G., Dees, E. C., Yuan, Y., Ueno, N. T., Pohlmann, P. R., Johnson, M. L., Chao, J., Shestova, O. E., Serody, J. S., et al. (2025) · Nature Medicine · doi:10.1038/s41591-025-03495-z · Cited by 268 · see citing works

Trial Watch: Adoptive cell transfer for oncological indications

Aranda, F., Buqué, A., Bloy, N., Castoldi, F., Eggermont, A. M. M., Cremer, I., Fridman, W. H., Fucikova, J. P., Galon, J., Špíšek, R., et al. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1046673 · Cited by 32 · see citing works

Chimeric Antigen Receptor– and TCR-Modified T Cells Enter Main Street and Wall Street

Barrett, D. M., Grupp, S. A., & June, C. H. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1500751 · Cited by 180 · see citing works

Clinical practice: chimeric antigen receptor (CAR) T cells: a major breakthrough in the battle against cancer

Lundh, S. M., Jung, I.-Y., Dimitri, A. J., Vora, A., Melenhorst, J. J., Jadlowsky, J. K., & Fraietta, J. A. (2020) · Clinical and Experimental Medicine · doi:10.1007/s10238-020-00628-1 · Cited by 10 · see citing works

Improving cell reinfusion to enhance the efficacy of chimeric antigen receptor T-cell therapy and alleviate complications

Han, Z., Ma, X., & Ma, G. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e28098 · Cited by 3 · see citing works

Abstract KN01: Updates on engineered T cells as cancer therapies

June, C. H. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.targ-15-kn01